Henri (Andy)

Henri (English: Atypical Ductal Hyperplasia, ADH) is an abbreviated name that characterizes Abnormal Development and Involution. It is used to identify benign breast tumors.

Henri is a proliferation of the mammary ductal epithelium. In this case, the cells look atypical, but not so much that a diagnosis of cancer can be made.

With Henri, there is an increase in the number of cells in the ducts and terminal units of the mammary gland. These changes are localized within the basement membrane.

Henri is often discovered incidentally during histological examination of breast tissue. This condition increases the risk of developing breast cancer in the future and requires regular monitoring and testing.

Henri (Andi): An innovative approach to the diagnosis and treatment of benign breast tumors

In the world of medicine, new methods and technologies are constantly being developed for early diagnosis and treatment of various diseases. One of these innovative approaches is Andi - an abbreviated name that characterizes Abnormal Development and Involution. This method is used to identify benign breast tumors, which allows for timely detection and treatment of this disease.

Abnormal development and involution refer to processes that occur in a woman’s body after birth and affect the condition of breast tissue. In some cases, these processes can lead to the formation of benign tumors. Tumors detected in the early stages have a high chance of being successfully treated and preventing the development of breast cancer.

Anri (Andi) includes several stages of research and diagnosis. The initial stage includes conducting a medical examination and collecting the patient's medical history. A detailed clinical examination is then performed, including mammography, ultrasound and magnetic resonance imaging of the breast. These methods provide detailed images of breast tissue and identify the presence of tumors.

However, the key component of Andi is the biopsy. A biopsy provides samples of tumor tissue for laboratory testing. Modern biopsy techniques include needle biopsy and core biopsy. The resulting tissue samples are analyzed for abnormal development and involution, which helps determine whether the tumor is benign.

Once the biopsy results are received, a team of specialists, including oncologists, radiologists and surgeons, discusses the most appropriate treatment plan for the patient. Depending on the size of the tumor, its morphological characteristics and the general condition of the patient, it may be decided to surgically remove the tumor or apply conservative treatment such as hormonal therapy or radiotherapy.

One of the main advantages of Andi is the early detection of benign breast tumors. Thanks to this method, doctors are able to begin treatment in the early stages of the disease, which increases the patient’s chances of a full recovery. Early detection also avoids the need for radical surgery and preserves the natural shape and function of the breast.

In addition, Anri (Andi) is a safe and non-traumatic diagnostic method. It does not cause discomfort in the patient and does not require a lot of time to conduct the study. This makes it more accessible and convenient for patients.

However, despite all the advantages, Andi is still a relatively new method and requires further research and clinical trials to confirm its effectiveness and reliability. It is also important to note that Andi is intended solely for the diagnosis of benign breast tumors, and cannot be used to detect malignant tumors.

In conclusion, Andi represents an innovative approach to the diagnosis and treatment of benign breast tumors. Through the use of various research methods, including biopsy, this approach allows for early detection of tumors and the most effective treatment. Although still in development, Andi provides new opportunities in the field of breast oncology and has the potential to significantly improve patient outcomes.

**Henri (or Andi) -** tumor lesion of the breast, characterized by a nonspecific clinical and morphological picture. Clinical manifestations of the disease may include changes in breasts of any size that are not associated with a violation of the integrity of the skin.

The occurrence of benign neoplasms in the thoracic region may be associated with age-related changes or functional overload of the body. The appearance of atypical cancer cells is also the cause of most malignant tumors. Histologically, the determination of the primary material is necessary to differentiate the disease without or with a low degree of malignancy of cells. However, it allows you to navigate the treatment tactics of a particular patient. At the same time, a biopsy and removal of the affected part is a prerequisite for a full study of the breast lesion and detection of cancer. *What types of Andi exist?* 1. Lipoma 2. Fibroma 3. Perinecytoma 4. Calcinosis 5. Giant cell tumor 6. Cystadenofibroma of the mammary gland 7. Adenofibrotic carcinoma (Fibroadenous carcinoma) 8. Mucinous breast cancer 9. Intracanalicular 10. Granular tumors 11 Cystic Adenous Mastopathy (Cytoadenoepithelioma) **Lipomas** are one of the most common gynecological diseases in women. They are genetic abnormalities in the development of cells that cannot fully function in the mammary glands. Histological diagnosis of lipoma includes: * identification of amorphous